I-MAB Biopharma Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2016-08-24
- Employees
- 251
- Market Cap
- $101.9M
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
- Conditions
- Solid Tumor Metastatic Cancer Advanced Cancer
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- I-Mab Biopharma US Limited
- Registration Number
- NCT05511350
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
- Conditions
- Ovarian CancerHead and Neck CancerNon Small Cell Lung CancerGastrointestinal CancerTriple Negative Breast CancerOvarian Carcinoma
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- I-Mab Biopharma US Limited
- Target Recruit Count
- 25
- Registration Number
- NCT05001347
- Locations
- 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States
A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: TJ210001 Injection
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- I-Mab Biopharma US Limited
- Target Recruit Count
- 25
- Registration Number
- NCT04947033
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
- Conditions
- Solid TumorAdvanced CancerMetastatic CancerEsophageal AdenocarcinomaGastric CancerGastroesophageal Junction Carcinoma
- Interventions
- Drug: TJ033721 (givastomig)Drug: TJ033721 (givastomig) , nivolumab, chemotherapy
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- I-Mab Biopharma US Limited
- Target Recruit Count
- 168
- Registration Number
- NCT04900818
- Locations
- 🇺🇸
Stern Center for Cancer Clinical Trials and Research, Orange, California, United States
🇺🇸UCHealth Cancer Care - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Horizon Oncology Research, LLC., Layfayette, Indiana, United States
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
- Conditions
- Cancer
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- I-Mab Biopharma US Limited
- Registration Number
- NCT04869501
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Arizona Oncology Associates, P.C., Tucson, Arizona, United States
- Prev
- 1
- 2
- Next
News
ALX Oncology's CD47 Inhibitor Combination with Keytruda Fails in Dual Phase II Trials
• ALX Oncology reported that its CD47-blocking agent in combination with Merck's Keytruda (pembrolizumab) failed to meet primary endpoints in two separate Phase II clinical trials. • The combination therapy was being evaluated in patients with head and neck squamous cell carcinoma and non-small cell lung cancer, representing a setback for the emerging CD47 inhibitor class. • This failure adds to mounting challenges in the CD47 inhibitor space, which has seen several clinical disappointments despite the target's promising role in cancer immune evasion mechanisms.